stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Return on equity
Royalty Pharma PLC's return on equity over the twelve months to 30 September 2026 was 0.00%, down 7.7 percentage points from fiscal 2025 (7.69%). Over the past ten years it has ranged from 0.00% (fiscal 2018) to 29.3% (fiscal 2019); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 7.69% | (0.72) |
| FY2024 | 8.41% | (3.16) |
| FY2023 | 11.6% | 11.14 |
| FY2022 | 0.43% | (5.72) |
| FY2021 | 6.15% | (6.01) |
| FY2020 | 12.2% | (17.13) |
| FY2019 | 29.3% | 29.29 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 18.4% |
| GMAB Genmab A/S Sponsored ADR compare | 14.0% |
| INCY Incyte Corporation compare | 7.84% |
| ARGX argenex SE compare | 0.00% |
| RPRX Royalty Pharma PLC | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| RVMD Revolution Medicines, Inc. compare | −93.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement